•
Mar 31, 2023

Radnet Q1 2023 Earnings Report

RadNet reported record first quarter revenue and adjusted EBITDA from imaging center operations and revised upwards 2023 financial guidance ranges for revenue and adjusted EBITDA.

Key Takeaways

RadNet reported a strong first quarter with a 14.3% increase in revenue to $390.6 million and adjusted EBITDA of $48.2 million. The company has revised its 2023 guidance upwards for revenue and adjusted EBITDA, reflecting confidence in its core imaging center business and strategic initiatives.

Revenue from the Imaging Center reporting segment increased by 13.9% to $388.4 million.

Adjusted EBITDA, excluding losses from the AI reporting segment, increased by 26.2% to $52.7 million.

Overall volume increased 14.0% over the prior year's first quarter.

The company revised upwards its 2023 financial guidance ranges for revenue and adjusted EBITDA.

Total Revenue
$391M
Previous year: $342M
+14.3%
EPS
-$0.08
Previous year: -$0.15
-46.7%
Imaging centers
363
Previous year: 351
+3.4%
Gross Profit
$38.7M
Previous year: $26.7M
+44.8%
Cash and Equivalents
$90.8M
Previous year: $70.7M
+28.5%
Total Assets
$2.41B
Previous year: $2.14B
+12.7%

Radnet

Radnet

Forward Guidance

RadNet has increased its guidance ranges for Revenue and Adjusted EBITDA to reflect the first quarter's strong financial results. The company is increasing its guidance levels for cash interest expense and capital expenditures to account for both the rising cost of interest and to fund the completion of certain de novo facilities.

Positive Outlook

  • Opportunities to expand operations in all markets organically.
  • Opportunities to expand operations through new acquisitions.
  • Opportunities to expand operations through joint ventures.
  • Expanding roll-out of the Enhanced Breast Cancer Detection (EBCD) program.
  • Innovating new features and capabilities of AI engines for breast, lung and prostate imaging.

Challenges Ahead

  • Economic environment.
  • Supply chain disruptions.
  • Inflation.
  • Possibility of further variants of COVID-19.
  • Rising cost of interest on debt.